PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
3110.63%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
11227.11%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
26362.71%
Interest expense growth above 1.5x AVXL's 14.01%. Michael Burry would check for over-leverage.
-84.19%
D&A reduction while AVXL shows 0.22% growth. Joel Greenblatt would examine efficiency.
-40.83%
EBITDA decline while AVXL shows 61.07% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Operating income decline while AVXL shows 63.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-16129.65%
Pre-tax income decline while AVXL shows 57.31% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense growth above 1.5x AVXL's 538.31%. Michael Burry would check for concerning trends.
-16129.65%
Net income decline while AVXL shows 58.15% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
EPS decline while AVXL shows 60.61% growth. Joel Greenblatt would examine position.
-12933.18%
Diluted EPS decline while AVXL shows 60.61% growth. Joel Greenblatt would examine position.
24.22%
Share count reduction below 50% of AVXL's 2.26%. Michael Burry would check for concerns.
24.22%
Diluted share reduction below 50% of AVXL's 2.26%. Michael Burry would check for concerns.